Jessica Hellyer
Medical Oncology · Philadelphia, PANPI 1235557398
Payments from drug & device makers
Across 159 payments — averaging $5124.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$358K
- Astrazeneca UK Limited$127K
- Amgen$93K
- Genentech, Inc.$85K
- Beone Medicines USA, Inc.$62K
- Beigene, Ltd.$54K
- plus $36K from 32 others
What the payments were for
- Consulting fees$11,53577%
- Speaking & faculty fees$1,0007%
- Food & beverage$2,27415%
- Education$811%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 17 | $357,900 |
| Astrazeneca UK Limited | 3 | $127,425 |
| Amgen | 1 | $93,264 |
| Genentech, Inc. | 19 | $84,682 |
| Beone Medicines USA, Inc. | 10 | $61,847 |
| Beigene, Ltd. | 10 | $53,533 |
| Mirati Therapeutics, Inc. | 8 | $11,954 |
| Tempus AI, Inc | 11 | $10,532 |
| Beigene USA, Inc. | 3 | $9,755 |
| Boehringer Ingelheim | 1 | $1,160 |
| E.r. Squibb & Sons, L.L.C. | 7 | $611 |
| Pfizer | 5 | $584 |
| Johnson & Johnson | 10 | $291 |
| Novartis | 8 | $175 |
| AVEO Pharmaceuticals, Inc. | 4 | $155 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $137 |
| Merck | 5 | $117 |
| Incyte Corporation | 3 | $66 |
| Array Biopharma Inc | 3 | $65 |
| Genentech USA, Inc. | 3 | $55 |
| Bristol Myers Squibb | 3 | $52 |
| Blueprint Medicines Corporation | 2 | $48 |
| Fennec Pharmaceuticals, Inc. | 2 | $45 |
| AbbVie | 2 | $42 |
| Syndax Pharmaceuticals, Inc. | 1 | $35 |
| Sobi, Inc | 1 | $31 |
| Iovance Biotherapeutics, Inc. | 1 | $29 |
| Astellas Pharma US Inc | 1 | $27 |
| Agios Pharmaceuticals, Inc. | 1 | $27 |
| Tersera Therapeutics LLC | 1 | $24 |
| GSK | 1 | $23 |
| Exelixis Inc. | 1 | $23 |
| Lilly USA, LLC | 1 | $22 |
| Puma Biotechnology, Inc. | 1 | $20 |
| Dendreon Pharmaceuticals LLC | 1 | $19 |
| Telix Pharmaceuticals | 1 | $16 |
| Regeneron Healthcare Solutions, Inc. | 1 | $16 |
| Gilead | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$814,820 in reported general payments places this provider in the 75th percentile of 238 medical oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CabometyxCabozantinib S-Malate | 17 | $403,873 |
| EliquisApixaban | 21 | $22,021 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 42 | $1,468 |
| Ondansetron OdtOndansetron | 71 | $1,281 |
| Prochlorperazine Maleate | 66 | $1,275 |
| Oxycodone Hcl | 68 | $862 |
| Gabapentin | 46 | $468 |
| Levothyroxine Sodium | 80 | $461 |
| Dexamethasone | 79 | $405 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 26 | $350 |
| Metoclopramide Hcl | 13 | $257 |
| Potassium Chloride | 17 | $250 |
| Baclofen | 12 | $127 |
| Olanzapine | 11 | $113 |
| Prednisone | 45 | $92 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Exelixis Inc.Cabometyx | $23 | $403,87317 claims |
| PfizerEliquis | $584 | $22,02121 claims |
| Lilly USA, LLCOlanzapine | $22 | $11311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 238 medical oncology providers in Pennsylvania.
Other medical oncology in Philadelphia
- Sukhmani PaddaPhiladelphia$25.6M
- Peter O DwyerPhiladelphia$18M
- Margaret von MehrenPhiladelphia$17.4M
- Kim Reiss BinderPhiladelphia$16.9M
- Carl JunePhiladelphia$13M
- Takami SatoPhiladelphia$11.5M
- Vivek NarayanPhiladelphia$10.6M
- Ubaldo Martinez-OutschoornPhiladelphia$10.5M
- Neil PalmisianoPhiladelphia$10.1M
- Anthony OlszanskiPhiladelphia$9.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.